Atara Biotherapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 10, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 10, 2026

ATRA$8.10-1.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(In thousands, except per share amounts)


· · September 30, · · December 31,
· · 2026 · · 2025
Assets
Current assets:
Cash and cash equivalents	$4,055	$8,482
Short-term investments	5,862	—
Accounts receivable	691	1,253
Other current assets	705	2,477
Total current assets	11,313	12,212
Property and equipment, net	38	73
Operating lease assets	6,494	7,064
Other assets	762	886
Total assets	$18,607	$20,235

Liabilities and stockholders’ equity (deficit)
Current liabilities:
Accounts payable	$762	$127
Accrued compensation	471	1,271
Accrued research and development expenses	24	82
Deferred revenue	513	716
Liability related to the sale of future revenues – current portion	1,105	9,750
Other current liabilities	3,693	2,976
Total current liabilities	6,568	14,922
Operating lease liabilities – long-term	8,482	9,347
Liability related to the sale of future revenues – long-term	39,560	32,673
Other long-term liabilities	1,899	1,795
Total liabilities	56,509	58,737

Commitments and contingencies (Note 9)

Stockholders’ equity (deficit):
Common stock—$0.0001 par value, 500,000 shares authorized as of September 30, 2026 and December 31, 2025; 10,188 and 7,324 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively	1	1
Additional paid-in capital	1,995,171	1,983,361
Accumulated other comprehensive income (loss)	(1)	1
Accumulated deficit	(2,033,073)	(2,021,865)
Total stockholders’ equity (deficit)	(37,902)	(38,502)
Total liabilities and stockholders’ equity (deficit)	$18,607	$20,235

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.